Liquid Handling System Market worth $7.79 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets projects the global liquid handling systems market will grow from $5.26 billion in 2026 to $7.79 billion by 2031, an 8.2% CAGR. Growth is expected to be led by automated systems (9.0% CAGR), pipettes (9.5%), genomics applications (9.0%), and expanding laboratory automation investment in Asia Pacific. The report also highlights a shift from manual tools toward higher-value robotic, electronic and software-integrated platforms, alongside targeted automation M&A including Ingersoll Rand's approximately $46.7 million acquisition of Scinomix in July 2026.

Analysis

This is not an earnings-moving data point for TMO, DHR, A, or GLW: liquid handling is too small and too diversified within their portfolios for a third-party TAM forecast to alter near-term estimates. The investable implication is mix, not headline growth—automation platforms pull through proprietary tips, plates, service, workflow software, and validation work, making recurring consumables and installed-base utilization more important than instrument shipments. TMO and DHR have the broadest ability to monetize the full workflow, while TECN has the most direct operating leverage if pharma/biotech capital spending and genomics throughput inflect.

The less obvious beneficiary is IR: its life-sciences automation build-out can create cross-selling into tube handling, labeling, and sample-traceability workflows, but the acquired asset base is far too small to justify a rerating absent disclosed organic-growth or margin contribution. Conversely, standalone pipette and commodity-consumable exposure faces pricing pressure as Asian lab build-outs favor local sourcing and as customers consolidate vendors around integrated automation ecosystems. Over the next 1-3 months, watch order intake, book-to-bill, and bioprocess/biopharma end-market commentary from TECN, TMO, DHR, and A; over 6-18 months, the key debate is whether automation growth converts into recurring consumables revenue rather than lumpy capital-equipment sales.

Consensus may over-extrapolate an automation narrative while underweighting funding cyclicality. Early-stage biotech funding, China tender budgets, and academic spending determine utilization and workstation purchases more than a published market-growth estimate; a weaker funding environment would first hit TECN and SRT3, which have greater exposure to high-growth life-science capex multiples. The thesis is falsified if major suppliers report sustained order growth without corresponding consumables/service acceleration, indicating customers are buying isolated hardware rather than adopting sticky integrated workflows.

Key Decisions for Investors

• No broad sector trade on this release; treat it as a watch item until 3Q/4Q order commentary validates improving automation demand rather than relying on consultant TAM estimates.
• Watch long TECN over a 6-12 month horizon only if quarterly order intake and book-to-bill turn sustainably positive; it offers the cleanest automation upside but also the highest sensitivity to biotech capex. Exit or avoid if management cuts organic-growth guidance or reports continued China/academic order weakness.
• Prefer TMO or DHR for lower-volatility exposure to laboratory-workflow automation over 12-18 months, with an emphasis on consumables and service attach-rate disclosures. The risk is that instrument placements rise while utilization remains weak, limiting the expected recurring-revenue conversion.
• Avoid using IR as a direct laboratory-automation proxy until management discloses material revenue, organic-growth, or margin contribution from its life-sciences platform; the strategic optionality is credible, but the current financial signal is insufficient.
• For a relative-value expression, consider long TMO / short SRT3 only after confirming renewed pharma-biotech spending: TMO has broader end-market and recurring-revenue diversification, while SRT3 remains more exposed to a multiple de-rating if growth fails to reaccelerate.